Literature DB >> 1654150

Frequent double infection with Epstein-Barr virus and human herpesvirus-6 in patients with acute infectious mononucleosis.

G Bertram1, N Dreiner, G R Krueger, A Ramon, D V Ablashi, S Z Salahuddin, N Balachandram.   

Abstract

Clinical infectious mononucleosis (IM) represents a benign self-limited form of lymphoproliferative disease which is usually caused by infection with Epstein-Barr virus (EBV). Microscopic characteristics of this lymphoproliferative disorder, however, are not ultimately specific for EBV infection, but can also be seen in infections with other lymphotropic viruses, especially of the herpesvirus family. Human herpesvirus-6 (HHV-6) infection can apparently be associated with a number of diseases also seen in EBV infection. Also, postinfectious chronic fatigue syndrome (PICFS) which may follow IM is in more than 60% of the cases accompanied by persistent active HHV-6 infection. We thus screened serologically 215 cases of acute IM for evidence for infection with EBV, HHV-6 and CMN. Patients were tentatively grouped into those having primary infection or reactivated (probably non-primary) infections. Cases were followed for two years to monitor changes in titers. Of all 215 cases, 211 (98.1%) were positive for EBV, 137 (63.7%) for primary infections, 21 (9.8%) for reactivated infection, and 53 (24.6%) for latent EBV. Thirty-three (15.3%) cases had primary HHV-6 infection, 63 (29.3%) active or reactivated HHV-6 infection, and 71 (33.9%) latent HHV-6. Double active EBV and HHV-6 infection, including primary and reactivated infections, amounted to 89 (39.5%) cases. Cytomegalovirus (CMV) antibody titers were found in 81 (37%) cases, 48 (22.3%) of which indicated latent infection and 33 (15.3%) active infection. Only two cases had evidence of active CMV infection alone, 1 cases of active CMV and HHV-6 infection. Serologic titers in 12 (5.6%) cases indicated combined active infection with CMV, EBV and HHV-6.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654150

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  7 in total

1.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 2.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 3.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  False positive immunoglobulin m antibody to cytomegalovirus in child with infectious mononucleosis caused by epstein-barr virus infection.

Authors:  Jee Min Park; Jae Il Shin; Jae Seung Lee; Young Ho Jang; Sung Hun Kim; Kang Hyuk Lee; Chang Hoon Lee
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

5.  Detection and typing of human herpesvirus 6 by molecular methods in specimens from patients diagnosed with encephalitis or meningitis.

Authors:  Norma P Tavakoli; Seela Nattanmai; Rene Hull; Heather Fusco; Lela Dzigua; Heng Wang; Michelle Dupuis
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

6.  Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters.

Authors:  J C Araujo; J Doniger; F Kashanchi; P L Hermonat; J Thompson; L J Rosenthal
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 7.  Lymphoproliferative Syndromes Associated with Human Herpesvirus-6A and Human Herpesvirus-6B.

Authors:  Eva Eliassen; Gerhard Krueger; Mario Luppi; Dharam Ablashi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-05-01       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.